Fosfomycin: Difference between revisions
(Text replacement - "*Diarrhea" to "*Diarrhea") |
|||
| (8 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Antibiotic]] | ||
*Dosage Forms: | *Dosage Forms: Oral, IV | ||
*Common Trade Names: Monurol | *Common Trade Names: Monurol (oral), Contepo (IV) | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Uncomplicated UTI: | *Uncomplicated UTI: 3g PO once | ||
**IDSA first-line recommendation | |||
**Typically reserved for ESBL E. coli | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* | *>12 y/o: 3 g PO x 1 | ||
>12 y/o: 3 g PO x 1 | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation Risk: Infant risk cannot be ruled out | ||
*Renal Dosing | *Renal Dosing: Half life increased in renal impairment, no specific adjustment | ||
*Hepatic dosing: no adjustment | |||
*Hepatic | |||
==Contraindications== | ==Contraindications== | ||
| Line 23: | Line 22: | ||
*Caution if hepatic impairment | *Caution if hepatic impairment | ||
*Caution if recent antibiotic-associated colitis | *Caution if recent antibiotic-associated colitis | ||
*Not the best antibiotic for severe infections (severe [[pyelonephritis]], [[urosepsis]], [[bacteremia]]). Consider an alternative if a patient is ill enough to require admission. | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 92: | Line 92: | ||
| ||[[Klebsiella]] sp||'''S''' | | ||[[Klebsiella]] sp||'''S''' | ||
|- | |- | ||
| ||E. coli/Klebsiella ESBL+||'''S''' | | ||E. coli/Klebsiella ESBL+||'''[[Has ESBL::S]]''' | ||
|- | |- | ||
| ||E coli/Klebsiella KPC+||'''S''' | | ||E coli/Klebsiella KPC+||'''S''' | ||
| Line 173: | Line 173: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 18:26, 10 December 2025
General
- Type: Antibiotic
- Dosage Forms: Oral, IV
- Common Trade Names: Monurol (oral), Contepo (IV)
Adult Dosing
- Uncomplicated UTI: 3g PO once
- IDSA first-line recommendation
- Typically reserved for ESBL E. coli
Pediatric Dosing
- >12 y/o: 3 g PO x 1
Special Populations
- Pregnancy Rating: B
- Lactation Risk: Infant risk cannot be ruled out
- Renal Dosing: Half life increased in renal impairment, no specific adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- Caution if hepatic impairment
- Caution if recent antibiotic-associated colitis
- Not the best antibiotic for severe infections (severe pyelonephritis, urosepsis, bacteremia). Consider an alternative if a patient is ill enough to require admission.
Adverse Reactions
Serious
- Angioedema
- Aplastic Anemia
- Asthma Exacerbation
- Hepatic Necrosis
- Toxic Megacolon
- C. difficile diarrhea
Common
- Diarrhea
- Vaginitis
- Rhinitis
- nausea
- headache
- dizziness
- back pain
- abdominal pain
- dysmenorrhea
Pharmacology
- Half-life: 5.7 hours
- Metabolism:
- Excretion: Urine 38%, Feces 18%
- Mechanism of Action: Bactericidal, inhibits cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014